14,184 Shares in Glaukos Corporation $GKOS Acquired by TD Asset Management Inc

TD Asset Management Inc bought a new position in shares of Glaukos Corporation (NYSE:GKOS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 14,184 shares of the medical instruments supplier’s stock, valued at approximately $1,157,000.

Other large investors have also modified their holdings of the company. UMB Bank n.a. grew its holdings in shares of Glaukos by 102.6% during the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 158 shares during the period. REAP Financial Group LLC acquired a new position in Glaukos in the third quarter valued at about $40,000. AlphaQuest LLC lifted its position in Glaukos by 5,754.5% in the second quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock valued at $67,000 after buying an additional 633 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in Glaukos by 16.2% during the second quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock worth $99,000 after buying an additional 136 shares during the period. Finally, SBI Securities Co. Ltd. increased its position in shares of Glaukos by 42.9% during the third quarter. SBI Securities Co. Ltd. now owns 1,205 shares of the medical instruments supplier’s stock valued at $98,000 after acquiring an additional 362 shares during the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. BTIG Research restated a “buy” rating and issued a $131.00 price objective on shares of Glaukos in a report on Wednesday, February 18th. The Goldman Sachs Group restated a “buy” rating and set a $138.00 target price on shares of Glaukos in a report on Friday, January 9th. Stifel Nicolaus increased their target price on shares of Glaukos from $115.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. William Blair raised Glaukos to a “strong-buy” rating in a research report on Friday, January 30th. Finally, Wells Fargo & Company lifted their target price on Glaukos from $122.00 to $135.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $133.69.

Insider Buying and Selling

In other Glaukos news, Director Gilbert H. Kliman sold 5,000 shares of Glaukos stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $107.27, for a total value of $536,350.00. Following the sale, the director owned 34,905 shares of the company’s stock, valued at approximately $3,744,259.35. The trade was a 12.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Thomas William Burns sold 186,945 shares of the stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $115.00, for a total value of $21,498,675.00. Following the transaction, the chief executive officer directly owned 153,775 shares of the company’s stock, valued at approximately $17,684,125. This trade represents a 54.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 325,000 shares of company stock worth $37,739,259. 5.80% of the stock is currently owned by insiders.

Glaukos Stock Down 2.8%

Shares of NYSE GKOS opened at $112.10 on Friday. The business has a 50-day moving average of $116.00 and a two-hundred day moving average of $100.74. The company has a market capitalization of $6.51 billion, a price-to-earnings ratio of -34.39 and a beta of 0.70. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $130.23. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.69 and a quick ratio of 4.06.

Glaukos (NYSE:GKOS) last issued its earnings results on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.06). The business had revenue of $143.12 million for the quarter, compared to analyst estimates of $132.16 million. Glaukos had a negative return on equity of 7.00% and a negative net margin of 36.99%.Glaukos’s revenue was up 35.6% on a year-over-year basis. During the same period last year, the business posted ($0.40) EPS. On average, analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.